COMING SOON: EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Terence Friedlander, MD, shares a look at an upcoming program reviewing recent, significant data from the EV-302/KEYNOTE-A39 study.

Related Keywords

Enfortumab Vedotin , ,Randomized Phase ,Previously Untreated Locally Advanced ,Metastatic Urothelial ,Urothelial Carcinoma ,Urothelial Cancer ,Advanced Or Metastatic Urothelial Carcinoma ,Ev 302 ,Keynote A39 ,